GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » PB Ratio

abrdn Life Sciences Investors (abrdn Life Sciences Investors) PB Ratio : 0.86 (As of Apr. 26, 2024)


View and export this data going back to . Start your Free Trial

What is abrdn Life Sciences Investors PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-26), abrdn Life Sciences Investors's share price is $12.97. abrdn Life Sciences Investors's Book Value per Share for the quarter that ended in Sep. 2023 was $15.00. Hence, abrdn Life Sciences Investors's PB Ratio of today is 0.86.

The historical rank and industry rank for abrdn Life Sciences Investors's PB Ratio or its related term are showing as below:

HQL' s PB Ratio Range Over the Past 10 Years
Min: 0.64   Med: 0.9   Max: 1.14
Current: 0.86

During the past 7 years, abrdn Life Sciences Investors's highest PB Ratio was 1.14. The lowest was 0.64. And the median was 0.90.

HQL's PB Ratio is ranked better than
65.72% of 1692 companies
in the Asset Management industry
Industry Median: 0.93 vs HQL: 0.86

During the past 12 months, abrdn Life Sciences Investors's average Book Value Per Share Growth Rate was -3.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -9.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -5.20% per year.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of abrdn Life Sciences Investors was -2.20% per year. The lowest was -9.50% per year. And the median was -2.20% per year.

Back to Basics: PB Ratio


abrdn Life Sciences Investors PB Ratio Historical Data

The historical data trend for abrdn Life Sciences Investors's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

abrdn Life Sciences Investors PB Ratio Chart

abrdn Life Sciences Investors Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
PB Ratio
Get a 7-Day Free Trial 0.91 0.87 0.98 0.88 0.83

abrdn Life Sciences Investors Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 0.96 0.88 0.86 0.83

Competitive Comparison of abrdn Life Sciences Investors's PB Ratio

For the Asset Management subindustry, abrdn Life Sciences Investors's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


abrdn Life Sciences Investors's PB Ratio Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's PB Ratio distribution charts can be found below:

* The bar in red indicates where abrdn Life Sciences Investors's PB Ratio falls into.



abrdn Life Sciences Investors PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

abrdn Life Sciences Investors's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2023)
=12.97/15.002
=0.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


abrdn Life Sciences Investors  (NYSE:HQL) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


abrdn Life Sciences Investors PB Ratio Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


abrdn Life Sciences Investors (abrdn Life Sciences Investors) Business Description

Traded in Other Exchanges
N/A
Address
1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.
Executives
Todd Reit director C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Bill Maher director 600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino director C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
James Joseph O'connor other: Director of Adviser C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc. other: Adviser 1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar officer: VP and Chief Legal Officer 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols other: Director of Adviser 1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard officer: President ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy officer: Secretary and Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari officer: Treasurer and CFO 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson officer: Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina officer: Chief Compliance Officer & VP 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Stephen Bird director 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10022

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Headlines

From GuruFocus

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 02-15-2023

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 08-17-2021

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 05-15-2023

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 12-31-2021

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 06-30-2021

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 08-16-2022

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 06-30-2020

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 01-06-2021

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 12-30-2022